Observational studyCancer science2023

Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer.

Yasushi Goto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.